This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010;10(2):91-2.

doi: 10.2165/11584910-000000000-00000.

Is it possible to accurately determine content of botulinum neurotoxin type A in drug products?

Dorothea Sesardic¹

Affiliations

Affiliation

¹ Division of Bacteriology, National Institute for Biological Standards and Control, Health Protection Agency, South Mimms, Hertfordshire, UK. Thea.Sesardic@nibsc.hpa.org.uk

PMID: 20698717
PMCID: PMC3585689
DOI: 10.2165/11584910-000000000-00000

Comment

Is it possible to accurately determine content of botulinum neurotoxin type A in drug products?

Dorothea Sesardic. Drugs R D. 2010.

. 2010;10(2):91-2.

doi: 10.2165/11584910-000000000-00000.

Author

Dorothea Sesardic¹

Affiliation

¹ Division of Bacteriology, National Institute for Biological Standards and Control, Health Protection Agency, South Mimms, Hertfordshire, UK. Thea.Sesardic@nibsc.hpa.org.uk

PMID: 20698717
PMCID: PMC3585689
DOI: 10.2165/11584910-000000000-00000

No abstract available

PubMed Disclaimer

Comment on

Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
Frevert J. Frevert J. Drugs R D. 2010;10(2):67-73. doi: 10.2165/11584780-000000000-00000. Drugs R D. 2010. PMID: 20698714 Free PMC article.

Similar articles

Consistent biochemical data are essential for comparability of botulinum toxin type A products.
Pickett A. Pickett A. Drugs R D. 2011;11(1):97-8; author reply 98-9. doi: 10.2165/11590750-000000000-00000. Drugs R D. 2011. PMID: 21410299 Free PMC article. No abstract available.
Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
Frevert J. Frevert J. Drugs R D. 2010;10(2):67-73. doi: 10.2165/11584780-000000000-00000. Drugs R D. 2010. PMID: 20698714 Free PMC article.
Xeomin is free from complexing proteins.
Frevert J. Frevert J. Toxicon. 2009 Oct;54(5):697-701. doi: 10.1016/j.toxicon.2009.03.010. Epub 2009 Mar 16. Toxicon. 2009. PMID: 19292989
The protein load of therapeutic botulinum toxins.
Pickett A, O'Keeffe R, Panjwani N. Pickett A, et al. Eur J Neurol. 2007 Apr;14(4):e11. doi: 10.1111/j.1468-1331.2007.01683.x. Eur J Neurol. 2007. PMID: 17388970 Review. No abstract available.
Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications.
de Almeida AT, De Boulle K. de Almeida AT, et al. J Cosmet Laser Ther. 2007;9 Suppl 1:17-22. doi: 10.1080/17429590701523794. J Cosmet Laser Ther. 2007. PMID: 17885882 Review.

See all similar articles

Cited by

Consistent biochemical data are essential for comparability of botulinum toxin type A products.
Pickett A. Pickett A. Drugs R D. 2011;11(1):97-8; author reply 98-9. doi: 10.2165/11590750-000000000-00000. Drugs R D. 2011. PMID: 21410299 Free PMC article. No abstract available.
Botulinum neurotoxin formulations: overcoming the confusion.
Samizadeh S, De Boulle K. Samizadeh S, et al. Clin Cosmet Investig Dermatol. 2018 May 30;11:273-287. doi: 10.2147/CCID.S156851. eCollection 2018. Clin Cosmet Investig Dermatol. 2018. PMID: 29910630 Free PMC article. Review.
Clinical relevance of botulinum toxin immunogenicity.
Benecke R. Benecke R. BioDrugs. 2012 Apr 1;26(2):e1-9. doi: 10.2165/11599840-000000000-00000. BioDrugs. 2012. PMID: 22385408 Free PMC article. Review.
Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.
Frevert J. Frevert J. Drugs R D. 2015 Mar;15(1):1-9. doi: 10.1007/s40268-014-0077-1. Drugs R D. 2015. PMID: 25559581 Free PMC article.

References

1. Frevert J. Content of botulinum neurotoxin in Botox®/ Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D. 2010;10(2):67–73. doi: 10.1007/BF03259776. - DOI - PMC - PubMed
1. Ekong TA, McLellan K, Sesardic D. Immunological detection of Clostridium botulinum toxin type A in therapeutic preparations. J Immunol Methods. 1995;180(2):181–91. doi: 10.1016/0022-1759(94)00313-L. - DOI - PubMed
1. Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet. 1994;344(8920):474–5. doi: 10.1016/S0140-6736(94)91806-6. - DOI - PubMed
1. McLellan K, Das RE, Ekong TA, et al. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon. 1996;34(9):975–85. doi: 10.1016/0041-0101(96)00070-0. - DOI - PubMed
1. Sesardic D, Leung T, Das Gaines R. Role of standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals. 2003;31(4):265–76. doi: 10.1016/j.biologicals.2003.08.001. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information